Centenial Surgic

Who are the top shareholders of the Centenial Surgic?

The top shareholders of Centenial Surgic are Vijay Kalidas Majrekar with 22.62%, and Kartik Shyam Kingar with 16.7%. Individual investors own a combined 50.29%, with no institutional holdings reported.

The top shareholders of Centenial Surgic include Vijay Kalidas Majrekar, who holds the highest promoter stake at 22.62%. The highest public shareholder is Kartik Shyam Kingar, with a holding of 16.7%. Additionally, individual investors collectively own 50.29% of the company. There are no institutional holdings from mutual funds or foreign institutional investors.

What does Centenial Surgic do?

Centenial Surgical Suture Ltd manufactures and sells surgical sutures in India, classified as a micro-cap company. As of March 2025, it reported net sales of 13 Cr and a net loss of 1 Cr, with a market cap of Rs 54 Cr.

Overview: <BR>Centenial Surgical Suture Ltd is engaged in the manufacture and sale of surgical sutures, operating within the healthcare services industry and classified as a micro-cap company.<BR><BR>History: <BR>Incorporated in 1995, Centenial Surgical Suture has been involved in the surgical suture market in India. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 13 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 54 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.39 <BR>Return on Equity: -5.20% <BR>Price to Book: 1.77<BR><BR>Contact Details: <BR>Address: Plot No F-29, MIDC Industrial Area Murbad Thane Maharashtra : 421401 <BR>Tel: 91-2524-222905/222906 <BR>Email: admin@centenialindia.com <BR>Website: http://www.centenialindia.com

Who are in the management team of Centenial Surgic?

As of March 2022, the management team of Centenial Surgic includes Vijay Majrekar (Chairman/Executive Director), Anuradha Kashikar (Executive Director/Whole Time Director), Devraj T Poojary (Executive Director/Whole Time Director), and four Independent Non-Executive Directors: B S Limaye, Sunil C Modi, Jagadish B Shetty, and N M Vora.

As of March 2022, the management team of Centenial Surgic includes the following individuals:<BR><BR>1. Vijay Majrekar - Chairman / Executive Director<BR>2. Anuradha Kashikar - Executive Director / Whole Time Director<BR>3. Devraj T Poojary - Executive Director & Whole Time Director<BR>4. B S Limaye - Independent Non-Executive Director<BR>5. Sunil C Modi - Independent Non-Executive Director<BR>6. Jagadish B Shetty - Independent Non-Executive Director<BR>7. N M Vora - Independent Non-Executive Director<BR><BR>These members play various roles in the company's governance and management structure.

Has Centenial Surgic declared dividend?

No Dividend History Available

Who are the peers of the Centenial Surgic?

Centenial Surgic's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Bandaram Pharma, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi. In terms of performance, Centenial Surgic has a 1-year return of 27.99%, higher than KMS Medisurgi's 0.00%, while Poly Medicure leads with a 24.29% return.

Peers: The peers of Centenial Surgic are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Bandaram Pharma, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average or Average management risk. Growth is Excellent at Bandaram Pharma, Average at Poly Medicure and Indegene, and Below Average at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Centenial Surgic, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, and Vijaya Diagnost., while Good is found at Centenial Surgic, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.29%, while KMS Medisurgi has the lowest at 0.00%. Centenial Surgic's 1-year return of 27.99% is higher than both. Additionally, Bandaram Pharma, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi have negative six-month returns.

Is Centenial Surgic overvalued or undervalued?

As of May 30, 2025, Centenial Surgic is considered very attractive and undervalued with a PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68, especially when compared to competitors like Max Healthcare and Apollo Hospitals, while also boasting a strong 1-year stock return of 40.95%.

As of 30 May 2025, the valuation grade for Centenial Surgic has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company appears to be undervalued, especially when considering its current PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68. These figures suggest that despite the negative earnings reflected in the PE ratio, the company's valuation metrics are more favorable compared to its peers.<BR><BR>In comparison to notable competitors, Max Healthcare has a PE ratio of 100.29 and an EV to EBITDA of 62.71, while Apollo Hospitals shows a PE of 69.03 and an EV to EBITDA of 34.71. This stark contrast highlights Centenial Surgic's attractive valuation relative to its peers in the healthcare services industry. Additionally, the company's strong stock performance, with a 1-year return of 40.95% compared to the Sensex's 7.62%, reinforces the narrative that it is currently undervalued in the market.

What is the technical trend for Centenial Surgic?

As of June 6, 2025, Centennial Surgic's technical trend is mildly bullish, supported by the weekly MACD and Bollinger Bands, although caution is advised due to mixed signals from the monthly indicators and short-term bearishness in daily moving averages.

As of 6 June 2025, the technical trend for Centenial Surgic has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the upward momentum. The Dow Theory also shows a mildly bullish stance on both weekly and monthly charts. However, the daily moving averages are mildly bearish, suggesting short-term weakness. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some mixed signals from the monthly indicators.

How big is Centenial Surgic?

As of 24th July, Centenial Surgical Suture Ltd has a market capitalization of 54.00 Cr, with recent net sales totaling 53.52 Cr and a net profit loss of 1.60 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Centenial Surgical Suture Ltd has a market capitalization of 54.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 53.52 Cr, while the sum of Net Profit for the same period reflects a loss of 1.60 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 30.75 Cr and Total Assets valued at 84.55 Cr.

How has been the historical performance of Centenial Surgic?

Centenial Surgic's historical performance shows fluctuating net sales, increasing from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, but it reported a loss with a profit after tax of -1.46 Cr in Mar'25, despite improved operating efficiency and cash flow from operations. Total liabilities and assets rose to 84.55 Cr in Mar'25, indicating financial challenges.

Answer:<BR>The historical performance of Centenial Surgic shows a fluctuating trend in net sales and profitability over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Centenial Surgic's net sales increased from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, following a dip in Mar'23. The total operating income also rose to 53.52 Cr in Mar'25 from 51.19 Cr in Mar'24. However, the company's total expenditure, excluding depreciation, increased slightly to 47.26 Cr in Mar'25 from 46.18 Cr in Mar'24. Operating profit, excluding other income, improved to 6.26 Cr in Mar'25 from 5.01 Cr in Mar'24, indicating better operational efficiency. Despite this, the company reported a profit before tax of -1.62 Cr in Mar'25, a decline from a profit of 1.27 Cr in Mar'24, leading to a profit after tax of -1.46 Cr in Mar'25 compared to 1.13 Cr in Mar'24. The total liabilities rose to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24, while total assets also increased to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24. The cash flow from operating activities improved to 17.00 Cr in Mar'25 from 6.00 Cr in Mar'24, but cash flow from investing activities was negative at -11.00 Cr. Overall, the company faced challenges in profitability despite an increase in sales and operating income.

When is the next results date for Centenial Surgical Suture Ltd?

The next results date for Centenial Surgical Suture Ltd is February 12, 2026.

The next results date for Centenial Surgical Suture Ltd is scheduled for February 12, 2026.

Are Centenial Surgical Suture Ltd latest results good or bad?

Centenial Surgical Suture Ltd's Q3 FY26 results show a net profit of ₹0.15 crore and a 21.80% revenue increase, indicating some recovery. However, concerns remain due to negative return on equity and poor stock performance compared to peers, suggesting investors should be cautious.

Centenial Surgical Suture Ltd's latest results for Q3 FY26 indicate a mixed performance. On the positive side, the company reported a net profit of ₹0.15 crore, marking a significant turnaround from a loss of ₹0.85 crore in the same quarter last year. Additionally, revenue grew by 21.80% year-on-year to ₹14.86 crore, which is the highest quarterly revenue in recent periods, and the operating margin improved to 10.30%.<BR><BR>However, despite these positive indicators, there are significant concerns regarding the company's overall financial health. The return on equity remains negative at -6.78%, and the five-year EBIT growth rate is troubling at -21.26%. The company's stock has also underperformed compared to its peers in the healthcare sector, declining 16.04% over the past year while the sector gained 25.64%.<BR><BR>In summary, while the latest quarterly results show some signs of recovery, the underlying issues related to profitability, capital efficiency, and market performance suggest that the company still faces substantial challenges. Investors may want to approach with caution given these mixed signals.

Should I buy, sell or hold Centenial Surgical Suture Ltd?

Why is Centenial Surgical Suture Ltd falling/rising?

As of 18-Apr, Centenial Surgical Suture Ltd's stock price is rising to 100.30, reflecting a 4.98% increase. Despite a history of underperformance, recent strong financial results and positive short-term momentum have contributed to the stock's current gains.

As of 18-Apr, Centenial Surgical Suture Ltd's stock price is rising, currently at 100.30, reflecting a change of 4.76 (4.98%) upward. The stock has shown strong performance over the past week, with a return of +9.89%, significantly outperforming the Sensex, which only increased by +1.22% during the same period. Additionally, the stock has gained 10.21% over the last two days, indicating a positive momentum.<BR><BR>Today's trading activity also supports the rise in stock price, as it opened with a gain of 4.67% and reached an intraday high of Rs 100.3. The stock's performance today has outperformed its sector by 3.48%. However, it is important to note that while the stock has shown recent gains, it has a history of underperformance, with a -25.43% return over the past year, which contrasts with the broader market's performance.<BR><BR>Positive factors contributing to the stock's rise include recent financial results that showed a significant growth in net sales and profitability metrics, with net sales growing at 21.80% and both profit before tax and profit after tax reaching their highest levels at Rs 0.15 crore. The stock is also trading at a discount compared to its peers, which may attract investors looking for value.<BR><BR>Despite these positive indicators, the company faces challenges, including weak long-term fundamental strength and a declining trend in operating profits over the last five years. Nevertheless, the recent positive financial results and short-term performance have led to the current rise in the stock price.

Which are the latest news on Centenial Surgic?